併用治療薬の上市：ブランド拡大とフランチャイズ開発戦略

Launching Combination Products: Brand extension and franchise development strategies

発行	Business Insights
出版日	2008年02月	商品コード	60584
ページ情報	英文 101 pages
価格	US$ 3,835 換算 ¥ 308,602 (税抜) PDF by E-mail (Single User License) US$ 14,382 換算 ¥ 1,157,319 (税抜) PDF by E-mail (Global License)

概要
原文目次
関連レポート

原文目次

Abstract

Combination pharmaceutical products, or fixed-dose combinations (FDC' s), offer benefits to many drug classes due to the additive nature of therapeutic effect and the reduced level of side-effects associated with their use. Their core advantage however is an improvement in convenience that stems from reducing prescription numbers and their associated administrative costs. Although fixed-dose combination drugs have historically attracted disapproval from physicians, who typically prefer to determine the components and ratios of drug applications at their own discretion, a widespread acknowledgement and acceptance of these therapies has now been established. This is largely due to their effectiveness in areas such as HIV and asthma, but the successful positioning of combination products remains difficult in therapeutic areas where combination therapies only provide marginally incremental benefits. Launching Combination Products is a new report published by Business Insights that provides detailed strategic guidance for the preparation and successful execution of combination product launches. This report performs a comprehensive examination of current competitive pressures, best practices and future developments in key therapeutic areas including cardiovascular, respiratory, HIV and women' s health. Detailed case studies also provide unique insights into the brand extension and franchise development strategies of leading companies and help to identify the key success factors behind recent combination product launches. Discover potential growth opportunities for your brands, identify future combination launches and use case studies to understand the most effective launch strategies across key therapeutic areas with this new report.

Executive Summary

An introduction to combination products
Combination product strategies in the cardiovascular market
Combination product strategies in the respiratory market
Combination product strategies in the diabetes market
Combination product strategies in the HIV market
Combination product strategies in the women' s health market
Combination product strategies in other therapeutic markets
Brand extension and franchise development strategies

Chapter 1 An introduction to combination products

Summary
Introduction
Therapeutic value
Combining therapies
Improved convenience
Commercial value
Brand extension
Franchise development
Leading combination products
Key products
Key therapeutic categories
Key combination product strategies

Chapter 2 Strategies for cardiovascular products

Summary
Introduction
Leading combination products
Recent combination product launches
Exforge
Future combination product developments
Simcor
Avandia/simvastatin
Key combination product launch strategies

Chapter 3 Strategies for respiratory products

Summary
Introduction
Leading combination products
Recent combination product launches
Symbicort
Future combination product developments
Singulair/Claritin
Flutiform
Key combination product launch strategies

Chapter 4 Strategies for diabetes products

Summary
Introduction
Leading combination products
Recent combination product launches
Janumet
Duetact
Future combination product developments
Avandia/simvastatin
Synordia
Key combination product launch strategies

Chapter 5 Strategies for HIV products

Summary
Introduction
Leading combination products
Recent combination product launches
Atripla
Future combination product developments
Key combination product launch strategies

Chapter 6 Strategies for women' s health

products
Summary
Introduction
Leading combination products
Recent combination product launches
Lybrel
Angeliq
Future combination product developments
Aprela
DUB-OC
Key combination product launch strategies

Chapter 7 Strategies for other therapeutic areas

Summary
Introduction
Leading combination products
Anti-infectives
Recent combination product launches
Combigan
Ziana
Pylera
Future combination product developments
Oncology
CNS and pain
Key combination product launch strategies

Chapter 8 Brand extension and franchise development strategies

Summary
Introduction
Case studies
Diovan, Diovan HCT/Co-Diovan and Exforge
Avandia, Avandamet and Avandaryl
Advair/Seretide
Case study: Kaletra
Case study: Vytorin
Key success factors
Branding
Pricing
Positioning

Chapter 9 Appendix

Sources
Product sales data
Regulatory data
Specific sources

List of Figures

Figure 1.1: Number of combination products by therapy area, 2006
Figure 1.2: Key combination product strategies
Figure 2.3: Key cardiovascular combination product strategies
Figure 3.4: Key respiratory combination product strategies
Figure 4.5: Key diabetes combination product strategies
Figure 6.6: Key women' s health combination product strategies
Figure 8.7: Diovan, Diovan HCT/Co-Diovan sales, 2002-2006
Figure 8.8: Avandia, Avandamet and Avandaryl sales, 2002-2006
Figure 8.9: Advair/Seretide, Flovent/Flixotide and Serevent sales, 2002-2006
Figure 8.10: Kaletra sales, 2002-2006
Figure 8.11: Vytorin, Zetia and Zocor sales, 2002-2006

List of Tables

Table 1.1: Leading brand extension combination products, 2006
Table 1.2: Leading brand extension combination products, 2006
Table 1.3: Leading franchise development combination products, 2006
Table 2.4: Leading brand extension combination products in the cardiovascular market, 2004-2006
Table 2.5: Leading franchise development combination products in the cardiovascular market, 2004-2006
Table 2.6: Recently approved combination products in the cardiovascular market, 2005-2007
Table 2.7: Future combination products in development for the cardiovascular market, 2007
Table 3.8: Leading brand extension combination products in the respiratory market, 2004-2006
Table 3.9: Leading franchise development combination products in the respiratory market, 2004-2006
Table 3.10: Recently approved combination products in the respiratory market, 2005-2007
Table 3.11: Future combination products in development for the respiratory market, 2007
Table 4.12: Leading brand extension combination products in the diabetes market, 2004-2006
Table 4.13: Recently approved combination products in the diabetes market, 2005-2007
Table 4.14: Future combination products in development for the diabetes market, 2007
Table 5.15: Leading franchise development combination products in the HIV market, 2004-200660
Table 5.16: Recently approved combination products in the HIV market, 2005-2007
Table 6.17: Leading brand extension combination products in the women' s health market, 2004-2006
Table 6.18: Leading franchise development combination products in the women' s health market, 2004-2006
Table 6.19: Recently approved combination products in the women' s health market, 2005-2007
Table 6.20: Future combination products in development for the women' s health market, 2007
Table 7.21: Leading brand extension combination products in other therapeutic markets, 2004-2006
Table 7.22: Leading franchise development combination products in other therapeutic markets, 2004-2006
Table 7.23: Recently approved combination products in other therapeutic markets, 2005-2007
Table 7.24: Future combination products in development for other therapeutic markets, 2007